Background: To assess efficacy and safety of treatment simplification to co-formulated Rilpivirine/Emtricitabine/Tenofovir (RPV/ FTC/TDF) in virologically suppressed patients. Materials and Methods: Endpoints of the analysis were: (a) treatment discontinuation of RPV/FTC/TDF for any reasons and (b) occurrence of virological failure (VF) defined as confirmed HIV-RNA 50 cp/mL). Results: Overall, 508 patients from five Italian reference centres were included: male gender 71.9%; median age 47 years (IQR 40Á52); IVDU as HIV risk 17.7%; HCV-AB positive 23.4%; CDC-C stage 17.5%; median CD4 cells/mL at switch 655 (IQR: 487Á843); median number of previous regimens three (IQR 2Á7). In a median follow-up of 196 days (IQR: 84Á287), 31 patients discontinued RPV/FTC/TDF (virological failure n05, hypersensitivity reaction n02, GI-toxicity n06, liver toxicity n01, CNStoxicity n 04, kidney toxicity n05, patient's decision/lost in follow-up n010). Moreover, VF occurred in eight patients (five discontinued regimen, while three remained on RPV/FTC/TDF). At survival analysis, the probabilities of treatment discontinuation or VF were 5.5% and 1.2% at 6 months, 13.2% and 2.8% at 12 months, respectively (Figure 1) . At adjusted Cox model, factors associated with discontinuation were: B200 CD4 cells/mL at switch (HR 5.3, 95% CI 1.1Á25.9, p00.038), number of pre-switch regimens (for each extra regimen: HR 1.05, 95% CI 1.01Á1.10, p00.024), male gender (HR 0.4, 95% CI 0.2Á0.9, p00.032). Only the number of pre-switch regimens was associated with VF (HR 1.13, 95% CI 1.06Á1.21, p 00.001). Type of pre-switch regimen was not associated with discontinuation or failure, but no VF was observed if switching from coformulated Efavirenz/FTC/TDF or from Raltegravir containing regimens. Switching to RPV/FTC/TDF led to significant improvement in fasting lipids levels: the decrease in cholesterol, LDL and triglycerides was observed switching from any regimen, but was more marked from boosted PI. In contrast, a moderate increase in transaminase (switching from all regimens except NNRTI-containing) and creatinine (except from TDF-containing regimens) were observed. Conclusions: Our data suggest that switching to RPV/FTC/TDF in virologically suppressed patients could be a good strategy with low risk of virological failure or treatment discontinuation; the switch is also associated with significant improvement in lipid profile.
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